ZA972345B - Use of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol in treating depressive disorders and bipolar disorders. - Google Patents

Use of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol in treating depressive disorders and bipolar disorders.

Info

Publication number
ZA972345B
ZA972345B ZA9702345A ZA972345A ZA972345B ZA 972345 B ZA972345 B ZA 972345B ZA 9702345 A ZA9702345 A ZA 9702345A ZA 972345 A ZA972345 A ZA 972345A ZA 972345 B ZA972345 B ZA 972345B
Authority
ZA
South Africa
Prior art keywords
disorders
piperidinemethanol
dimethoxyphenyl
fluorophenyl
ethyl
Prior art date
Application number
ZA9702345A
Other languages
English (en)
Inventor
Cesare Mondadori
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Publication of ZA972345B publication Critical patent/ZA972345B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA9702345A 1996-03-21 1997-03-18 Use of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol in treating depressive disorders and bipolar disorders. ZA972345B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96400591A EP0796619A1 (en) 1996-03-21 1996-03-21 Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders

Publications (1)

Publication Number Publication Date
ZA972345B true ZA972345B (en) 1997-09-25

Family

ID=8225234

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9702345A ZA972345B (en) 1996-03-21 1997-03-18 Use of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol in treating depressive disorders and bipolar disorders.

Country Status (23)

Country Link
US (2) US6022877A (pt)
EP (2) EP0796619A1 (pt)
JP (1) JP4165906B2 (pt)
KR (1) KR100423018B1 (pt)
CN (1) CN1114406C (pt)
AR (1) AR006281A1 (pt)
AT (1) ATE219672T1 (pt)
AU (1) AU704435B2 (pt)
BR (1) BR9708109A (pt)
CA (1) CA2250077C (pt)
DE (1) DE69713571T2 (pt)
DK (1) DK0888114T3 (pt)
ES (1) ES2175356T3 (pt)
HK (1) HK1019702A1 (pt)
HU (1) HU226675B1 (pt)
IL (1) IL126022A (pt)
NO (2) NO316788B1 (pt)
NZ (1) NZ331448A (pt)
PT (1) PT888114E (pt)
SI (1) SI0888114T1 (pt)
TW (1) TW517048B (pt)
WO (1) WO1997034603A1 (pt)
ZA (1) ZA972345B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0796619A1 (en) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders
TWI249526B (en) * 1998-03-13 2006-02-21 Aventis Pharma Inc Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
US6713627B2 (en) 1998-03-13 2004-03-30 Aventis Pharmaceuticals Inc. Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
US6277864B1 (en) 1998-08-28 2001-08-21 Aventis Pharmaceuticals Inc. Use of R- +)-α-(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol for the treatment of sleep disorders
DE69911436T2 (de) * 1998-08-28 2004-07-01 Aventis Pharmaceuticals Inc. Die verwendung von r (+)- g(a)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol zur behandlung von obstruktive schlafapnoe
US6939879B2 (en) 1998-08-28 2005-09-06 Aventis Pharmaceuticals Inc. Use of R (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia
US20020099076A1 (en) * 2000-05-25 2002-07-25 Richard Scheyer D. Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis
US20020161026A1 (en) * 2000-11-07 2002-10-31 Paralkar Vishwas M. Combination therapies for the stimulation of bone growth
DE60113731T2 (de) * 2001-01-31 2006-06-29 Pfizer Products Inc., Groton Als inhibitoren von pde4-isozymen geeignete etherderivate
US8501778B2 (en) 2008-06-20 2013-08-06 Nhwa Pharma. Corporation Aralkyl piperidine derivatives and their uses as antalgic or ataractic agent
US8188119B2 (en) * 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169096A (en) * 1985-07-02 1992-12-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl-piperidine-methanol derivatives
US4783471A (en) * 1985-07-02 1988-11-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl piperidine methanol derivatives and the uses thereof
US4912117A (en) * 1985-07-02 1990-03-27 Merrell Dow Pharmaceuticals Inc. Novel chemical compounds
US5021428A (en) * 1985-07-02 1991-06-04 Merrell Dow Pharmaceuticals Inc. Novel chemical compounds for the prophylactic treatment of migraine
US4762842A (en) * 1985-10-01 1988-08-09 Eli Lilly And Company Selective method for blocking 5HT2 receptors
US4877798A (en) * 1987-11-23 1989-10-31 Merrell Dow Pharmaceuticals Inc. Treatment of fibromyalgia
JPH02138214A (ja) * 1987-12-10 1990-05-28 Merrell Dow Pharmaceut Inc 不安を治療する方法
ATE102482T1 (de) * 1988-01-21 1994-03-15 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-piperidinyl- verbindungen zur herstellung eines arzneimittels zur behandlung von schlaflosigkeit.
US5064838A (en) * 1988-01-21 1991-11-12 Merrell Dow Pharmaceuticals 1,4-disubstituted-piperidinyl compounds as pain relievers
ZA891901B (en) * 1988-03-17 1989-11-29 Merrell Dow Pharma Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy
US4902691A (en) * 1988-12-19 1990-02-20 Eli Lilly And Company Heteroalkylamides of (8-β)-1-alkyl-6-(substituted)ergolines useful for blocking 5HT2 receptors
US5106855A (en) * 1989-12-20 1992-04-21 Merrell Dow Pharmaceuticals Inc. Method for the treatment of glaucoma
DE69105501T2 (de) * 1990-06-01 1995-04-13 Merrell Dow Pharma (+)-alpha-(2,3 dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinmethanol.
US5643784A (en) * 1990-12-04 1997-07-01 H, Lundbeck A/S Indan derivatives
US5618824A (en) * 1994-03-09 1997-04-08 Merrell Pharmaceuticals Inc. Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
HUP9903684A3 (en) * 1995-12-22 2001-12-28 Lilly Co Eli Use of olanzapine for the preparation of pharmaceutical compositions treating depression
EP0796619A1 (en) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders

Also Published As

Publication number Publication date
IL126022A (en) 2003-11-23
CN1213968A (zh) 1999-04-14
DE69713571T2 (de) 2003-02-20
HU226675B1 (en) 2009-06-29
CA2250077C (en) 2003-10-07
US6022877A (en) 2000-02-08
CN1114406C (zh) 2003-07-16
NO984348L (no) 1998-09-18
JP4165906B2 (ja) 2008-10-15
KR20000064711A (ko) 2000-11-06
KR100423018B1 (ko) 2004-05-17
IL126022A0 (en) 1999-05-09
NO20033184D0 (no) 2003-07-11
NO20033184L (no) 1998-09-18
ES2175356T3 (es) 2002-11-16
DK0888114T3 (da) 2002-10-07
NZ331448A (en) 2000-06-23
NO316788B1 (no) 2004-05-10
JP2000506887A (ja) 2000-06-06
AR006281A1 (es) 1999-08-11
BR9708109A (pt) 1999-07-27
EP0888114B1 (en) 2002-06-26
CA2250077A1 (en) 1997-09-25
TW517048B (en) 2003-01-11
DE69713571D1 (de) 2002-08-01
HUP9902135A2 (hu) 1999-11-29
ATE219672T1 (de) 2002-07-15
US6380216B1 (en) 2002-04-30
HUP9902135A3 (en) 2001-05-28
AU704435B2 (en) 1999-04-22
EP0796619A1 (en) 1997-09-24
HK1019702A1 (en) 2000-02-25
EP0888114A1 (en) 1999-01-07
PT888114E (pt) 2002-11-29
WO1997034603A1 (en) 1997-09-25
NO984348D0 (no) 1998-09-18
AU1963197A (en) 1997-10-10
SI0888114T1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
EP0531410A4 (en) (+)--g(a)-(2,3-dimethoxyphenyl)-1- 2-(4-fluorophenyl)ethyl)-4-piperidinemethanol
HK1034906A1 (en) Method and composition of an oral preparation of itraconazole.
ZA972345B (en) Use of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol in treating depressive disorders and bipolar disorders.
AU5774699A (en) Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders
CY2482B1 (en) Paroxetine in treatment of depression.
IL111554A0 (en) Methods and compositions for hair treatment
AU3204899A (en) Hair treatment composition and method
IL138307A0 (en) PROCESSES FOR THE PREPARATION OF (R)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL) ETHYL]-4-PIPERIDINEMETHANOL
BG104914A (en) Paroxetine maleate
AU5974999A (en) Hair treatment composition, method and use
HUP0202145A3 (en) The use of r(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of sleep disorders
AU2295497A (en) Therapeutic and preventive method against harmful microbes
ZA974386B (en) New formulation for treatment of thromboembolism.
GB9603766D0 (en) 2-(Fluroenonyl) - carbapenems, compositions and methods of use
ZA989842B (en) Esters of (+)-Ó-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol.
NZ328739A (en) Treatment of estrogen therapy using 8,9-dehydroesterone
BR1100532A (pt) (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorfenil)etil]-4-pipe ridinometanol e composição contendo o mesmo
AU5729896A (en) Improved dental implant process and treated prosthetic
ZA991907B (en) Novel processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol.